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patients in whom treatment was successful
CEA excretion declined, contrary to the
remainder of this group, who showed both
progression of the disease and increase of
CEA.
It is concluded that CEA estimations are
highly valuable for diagnostic and follow-up
purposes in patients with bladder carcinoma
provided that urinary infections are absent.
RADIOIMMUNOASSAY OF HCG, of
AND f SUBUNITS IN CANCER. P.
FRANCHIMONT and A. REUTER. Institute of
Medicine, University of Liege, Belgium.
The specific measurement of ,B HCG and
native HCG is possible. We have prepared a
specific antiserum anti-HCG which does not
give any cross-reaction either with the other
glycoprotein hormones (follicle stimulating
hormone, FSH, luteinizing hormone, LH,
thyrostimulating hormone, TSH) or with cx
and ,8 subunits of HCG.
Another method for assaying native HCG
is to use a system constituted of labelled f
subunit with an anti-: subunit antiserum and
pure HCG as standard preparation. For the
specific measurement of P HCG subunit, we
use a homologous system in which the
glycoprotein hormones as well as of and P LH
subunits do not interfere. For the measure-
ment of the of subunit we have a less specific
system. However, correction is possible
knowing the normal interference in the sera
of normal healthy subjects and not pregnant
subjects.
Using these methods, we have detected
HCG, a and f subunits ofHCG in pathological
ranges in 81%, 100% and 75% in tropho-
blastic and embryonic tumours (21 cases)
respectively. In 78 patients with non-
trophoblastic tumours, native HCG ay and P
subunits HCG were respectively detected in
11%, 110% and 24% of the cases.
VAGINAL CYTOLOGIC EVALUATION
AS A PREDICTIVE TEST ON HOR-
MONE DEPENDENCY AND RESPON-
SIVENESS TO PROGESTOGENS OF
ENDOMETRIAL ADENOCARCINOMA.
P. IDE and J. BONTE. University of Louvain,
Belgium.
Progestogens seem to be very useful not
only as a complement to combined radio-
surgical therapy of localized endometrial
adenocarcinoma but also as an exclusive
treatment of recurrent or metastatic cancers.
Exclusive high dosage medroxyprogesterone
treatment brings about a significant remission
in almost 50% of the recurrent or metastatic
endometrial adenocarcinomata. Vaginal cy-
tological evaluation before andduringtherapy
has a striking prognostic value. In 57% of
the patients presenting an oestrogenic vaginal
smear (68% of total patient number) before
medroxyprogesterone treatment a significant
tumourremission is observed. Progestational
treatment changinganoestrogenic smeartoan
intermediate or to an atrophic one, or bring-
ing an intermediate smear to atrophy induces
a 92%, even a 100%, significant remission
rate. Return of the vaginal smear to an
oestrogenic aspect after withdrawing the
medroxyprogesterone therapy, or even during
this treatment, announces a new progression
of the adenocarcinoma.
CHARACTERIZATION OF IMMUNO-
COMPETENCE IN CANCER PAT-
IENTS. F. DE HALLEUX, C. DECKERS,
M. T. SIMON-MEULENBERGS and H. MAISIN.
Institut du Cancer, Louvain, Belgium.
Aiming towards a thorough evaluation of
the prognosis and the immunological ap-
proach of the therapy of cancer patients,
nonspecific as well as specific immune re-
actions have been investigated by in vivo and
in vitro tests.
The anamnestic response to PPD (purified
protein derivative) tuberculin was investi-
gated by Mantoux tests and leucocyte migra-
tion tests. The results show that for 19/38
patients with a positive Mantoux test the
average migration inhibition index was
12-43%. The 19 negative patients had an
average index of 1-23%. A primary response
was investigated by cutaneous sensitization
to DNCB (dinitrochlorobenzene). The
specific immune reactions were tested by
51Cr-release lymphocytotoxicity assay
against allogeneic tumour cells of the same
histological type. The lymphocytotoxicity
indices were above 30% for 6/10 melanoma
patients and 1/6 breast tumour patients.
No healthy individual nor patient with
unrelated tumour had an index above 28%.
Some correlation between these results and
the clinical status of the patients has been
observed, however, larger series will be needed
for demonstrative evidence.